## 510(k) SUMMARY

Submitter Information: TOTOKU ELECTRIC CO., LTD.

300 Oya, Ueda

Nagano 386-0192 Japan

Contact Person: Mikio Hasegawa, General Manager

Email: hasegawam@totoku.co.jp

+81.268.34.5469 Tel: Fax: +81.268.34.5565

Date Prepared: March 7, 2005

Device Name: 21.3-inch (54cm) Monochrome LCD Monitor MDL2109A (ME251i) (DV2MM-HB)

Common Name: MDL2109A, ME251i, DV2MM-HB, 2M Monitor/Display

Classification Name:

Class II

(Part892 Radiology Devices

Sec. 892.2050 Picture Archiving and Communication System)

Predicate Device: MDL2108A (K040695)

Device Description:

MDL2109A (ME251i) (DV2MM-HB) is a 21.3-inch Monochrome LCD Monitor that supports DVI video signal and provides UXGA (1200  $\times$  1600) resolution

for both landscape and portrait display.

Intended Use: 21.3-inch (54cm) Monochrome LCD Monitor MDL2109A (ME251i) (DV2MM-HB) is to be used in conjunction with the picture archiving communication system (PACS) for medical imaging applications. It is not meant to be used for digital

mammography.

Substantial Equivalence: MDL2109A (ME251i) (DV2MM-HB) has almost the same characteristics as

TOTOKU's predicate device MDL2108A (K040695) except for the molds and

the front sensor, which has been newly placed.



APR 2 2 2005

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Mikio Hasegawa General Manager TOTOKU Electric Co., Ltd MM Company, Design Group 300 Oya, Ueda, Nagano 386-0192 **JAPAN** 

Re: K050617

Trade/Device Name: 21.3-inch (54cm) Monochrome LCD

Monitor MDL2109A (ME251i) (DV2MM-HB)

Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications systems

Regulatory Class: II Product Code: LLZ Dated: March 7, 2005 Received: March 10, 2005

## Dear Mr. Hasegawa:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

| 21 CFR 876.xxxx<br>21 CFR 884.xxxx<br>21 CFR 892.xxxx | (Gastroenterology/Renal/Urology)<br>(Obstetrics/Gynecology)<br>(Radiology) | 240-276-0115<br>240-276-0115<br>240-276-0120<br>240-276-0100 |
|---|--|--|
| Other   |  |  |

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Manay C. Brogdon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

## **INDICATIONS FOR USE**

| 510(k) Number: Not Known      |                |                                       |
|-------------------------------|----------------|---------------------------------------|
| Device Name: 21.3-inch (54cm) | Monochrome L   | .CD Monitor MDL2109A                  |
| (ME251i) (DV2MM               | І-НВ).         |                                       |
|                               |                |                                       |
| indications for use:          |                |                                       |
|                               |                |                                       |
|                               |                | <u> </u>                              |
| 21.3-inch (54cm) Monochrome   | LCD Monitor N  | MDL2109A (ME251i) (DV2MM-HB) is to be |
|                               |                | ving communication systems (PACS) for |
|                               |                | o be used for digital mammography.    |
|                               |                |                                       |
|                               |                |                                       |
|                               |                |                                       |
|                               |                |                                       |
| /                             |                |                                       |
| Prescription Use              | AND/OR         | Over-The-Counter Use                  |
| (Part 21 CFR 801 Subpart D)   |                | (21 CFR 807 Subpart C)                |
|                               |                |                                       |
| (PLEASE DO NOT WRITE BELOW    | THIS LINE-CO   | NTINUE ON ANOTHER PAGE OF NEEDED)     |
|                               |                |                                       |
|                               |                |                                       |
| Concurrence of                | CDRH, Office o | f Device Evaluation (ODE)             |
| • H                           |                |                                       |

(Division Sign-Off)
Division of Reproductive, Abdominal,

and Radiological Devices K0506/7